Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nomination committee ahead of 2022 Annual General Meeting of Vitec Software Group AB (publ)

In accordance with the decision of the Annual General Meeting, the Nomination Committee for Vitec Software Group AB (publ) has been appointed ahead of the Annual General Meeting 2022.The Nomination Committee consists of the following members: Olov Sandberg, Chairman of the Nomination CommitteeLars Stenlund (Chairman of the Board)Jerker Vallbo On August 31, 2021, the above Nomination Committee represented together about 49% of the votes in Vitec Software Group AB (publ). The Annual General Meeting of Vitec will be held on Tuesday, April 26, 2022, in Umeå, Sweden. Shareholders

BioStock: CombiGene’s scientific founders on the agreement with Spark

Recently, gene therapy company CombiGene signed an exclusive global license agreement for their gene therapy candidate CG01 with Spark Therapeutics. The deal is potentially worth $328.5 million excluding royalties. Much has happened since CombiGene was formed and BioStock turned to the scientific founders Professor Merab Kokaia and Associate Professor David Woldbye, for a comment on the company’s development.Read the full interview with Merab Kokaia and David Woldbye at biostock.se: https://www.biostock.se/en/2021/10/combigenes-scientific-founders-on-the-agreement-with-spark/ This is

Dignitana honors young breast cancer survivor Maricel Otero as a DigniCap Dignitary

“If I can make it through cancer with my faith, I can make it through anything.”Dignitana , world leader in scalp cooling innovation, has appointed Maricel Otero, breast cancer survivor and wellness advocate of Orlando, Florida, as its latest DigniCap Dignitary, the company’s patient advocacy and ambassador program. In this role, Otero will share insights from her individual experience with breast cancer in an effort to help others navigate their own experiences. In recognition of Breast Cancer Awareness Month, Otero will be

Brødrene Dahl and Avensia launch market leading B2B e-commerce experience

One of Norway’s largest B2B e-commerce merchants Brødrene Dahl  has recently launched a new e-commerce site together with modern commerce expert Avensia. The goal is clear and ambitious: to offer the best B2B customer experience in the country.As part of Brødrene Dahl's goal to make customers’ everyday work life easier the company is on a mission to level-up and modernize their digital sales channel. The focus of the new e-commerce site is to deliver high quality customer experiences including best-in-class site speed, efficient product search functionality as well as

Saab enter Memorandum of Understanding to Develop the Next Generation of Maritime Communication Services

Saab AB, has entered a Memorandum of Understanding to cooperate with ORBCOMM and AAC Clyde Space AB to develop the next generation of global maritime communication services based on a VHF Data Exchange System (VDES). The parties, collaborating under a new brand named AOS, aim both for services directed to end customers as well as for safety of navigation services. The goal of the consortium is to create a global maritime communication network enabling ship-to-ship and ship-to-shore communication everywhere on the globe.The cooperation will occur in phases, including both terrestrial and

Cyxone announces promising preclinical results supporting T20K combination therapy for multiple sclerosis

Cyxone (publ) announces today that the company, together with its academic partner Medical University of Vienna, has continued to investigate the drug candidate T20K in combination with a kappa opioid receptor agonist. A combination which in pre-clinical experiments demonstrate promising synergistic therapeutic effects and potential disease modifying features in multiple sclerosis. The results build upon previous data which underpin a patent application to the European Patent Office that recently was made public.Multiple sclerosis (MS) is a chronic autoimmune disease that emerges when the

Biomaster protected children's ride-on luggage wins design award

Biomaster partner Trunki has won a Silver-medal at the 10th Annual Junior Magazine Design Awards with the antimicrobial children’s luggage ‘Abbie the Ambulance’. Trunki, the UK company behind the original ride-on luggage, was honoured in the Best Children’s Backpack/Suitcase Design category. The first of her kind, Abbie the Ambulance is made with built in Biomaster technology which inhibits the growth of harmful microbes on surfaces. The protection works 24/7 and is effective for the lifetime of the product. Abbie is manufactured from lightweight plastic and is covered by a 5-year

Idogen publishes interim report for 1 January – 30 September 2021

Idogen AB's interim report for January to September 2021 is available on the company's website https://idogen.com/en/investors/financial-reports/ Third quarter (July-September 2021)•  Övriga rörelseintäkter uppgick till 7 171 (1 968) TSEK.•  Rörelseresultatet uppgick till -5 249 (-4 779) TSEK.•  Periodens resultat uppgick till -5 191 (-4 729) TSEK.•  Kassaflödet från den löpande verksamheten uppgick till -9 029 (-6 864) TSEK.•  Resultat per aktie före utspädning uppgick till -0,28 (-0,52) SEK. Resultat per aktie efter utspädning uppgick till -0,28 SEK (-0,52). Period (

BioStock: Coegin Pharma receives final approval for COAK Study

After complying with the conditions given by the Danish Ethics committee in September, Nordic biotech Coegin Pharma has received the final approval for initiating the phase I/II COAK study in actinic keratosis patients. From the beginning of November, the company will begin patient recruitment, and thus take an important step towards developing a novel treatment for a disease with a large unmet medical need.Read the full article at biostock.se: https://www.biostock.se/en/2021/10/coegin-pharma-receives-final-approval-for-coak-study/ This is a press release from BioStock - Connecting

UPM Interim Report Q3 2021: UPM delivers a record quarter in an exceptionally volatile global environment

UPM-Kymmene Corporation        Stock Exchange Release (Interim Report) 26 October 2021 at 09:45 EEST UPM Interim Report Q3 2021:UPM delivers a record quarter in an exceptionally volatile global environment Q3 2021 highlights · Sales increased by 24% to EUR 2,523 million (2,028 million in Q3 2020) · Comparable EBIT increased by 98% to EUR 424 million, 16.8% of sales (215 million, 10.6%) · Operating cash flow was EUR 318 million (365 million) · Demand for UPM’s products was good, and overall, price increases more than offset the rapid rise in input costs · UPM

AegirBio terminates distribution agreement with NowMed Sweden AB

The board of directors of AegirBio has now received the results of the internal investigation concerning the company’s distributor, which was carried out by external parties. As a consequence hereof, AegirBio terminates the distribution agreement with NowMed Sweden AB.AegirBio is taking control over the company’s distribution in Asia until an agreement is signed with a new distributor. NowMed Sweden AB is working on transferring all purchase orders from the local distributor to AegirBio, including the purchase order that has already been sent to Thailand. AegirBio is now establishing a

Proact to acquire ahd and strengthen its managed cloud services offering in Germany

Today Proact has signed a definite agreement to acquire German IT company ahd GmbH & Co. KG, a specialist in managed services, offering cloud solutions, consulting and on-premises services for its customers. The acquisition, that is expected to close during the day, will strengthen Proact's capabilities and presence in the German market.Acquisitions are an important part of Proact's growth strategy, with the purpose of broadening its services and expanding its business in the company's key markets. ahd will be the fourth acquisition over a two-year period wherein Proact acquired PeopleWare

Atlas Copco appoints Eva Klasén Senior Vice President, Chief Legal Officer

Nacka, Sweden, October 26, 2021: Atlas Copco has appointed Eva Klasén Senior Vice President, Chief Legal Officer and member of Atlas Copco’s Group Management. Eva Klasén will assume her new role May 1[st], 2022.Since January 2021, Eva Klasén is Vice President, Deputy Chief Legal Officer at Atlas Copco AB. She joined Atlas Copco in 2000 as Assistant Corporate Counsel and has since then held several positions in the legal functions in both Sweden and China. “Eva is a highly valued colleague with a solid legal background and experience”, says Mats Rahmström, President and CEO of the Atlas

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 25th October 2021, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 26,067,785 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Brunswick Real Estate’s lending fund increases by SEK 1 billion

Brunswick Real Estate Capital (” Brunswick”) has grown its third senior debt property fund by SEK 1,1 billion through investments by, among other actors, the Swedish health care group Praktikertjänst’s pension foundation. The investments are further evidence of the rising interest in property debt funds as a complement to traditional fixed-income investments.The third fund now amounts to SEK 13,4 billion a record high level for a Nordic senior debt property fund. The capital raising was listed among the top 10 in Europe. So far this year, Brunswick has lent over SEK 2,2 billion of which 50

Interim report January – September 2021

Third quarter 2021 · Net sales increased to SEK 3,215m (3,105) corresponding to organic sales growth of 3%. · Operating profit increased to SEK 228m (195), corresponding to an operating margin of 7.1% (6.3). · Changes in exchange rates positively impacted operating profit by SEK 5m. · Profit after tax amounted to SEK 170m (132), corresponding to earnings per share after dilution of SEK 1.01 (0.78). · Operating cash flow amounted to SEK 123m (484).The Nordic and Central European kitchen markets remained strong following the underlying demand for home renovations. In the UK,

Sedana Medical’s Nomination committee appointed

Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 10, 2021, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee.Sedana Medical's Nomination Committee for the 2022 Annual General Meeting consists of: · Thomas Eklund, Chairman of the Board · Karl Tobieson,

BioStock: BibbInstruments aims high in cancer diagnostics industry

Early detection and diagnostics of cancer is one of the best tools for combating what remains one of the world’s deadliest diseases. Swedish medtech company BibbInstruments develops the EndoDrill Model X, a medical device with the potential to make a significant dent in the cancer diagnostics industry while addressing a market potentially worth close to 1 billion USD, according to the company.Read the article at biostock.se: https://www.biostock.se/en/2021/10/bibbinstruments-aims-high-in-cancer-diagnostics-industry/ This is a press release from BioStock - Connecting Innovation &

Gapwaves receives a new order from HELLA

Gapwaves has received a follow-up order for a project for 77 GHz antennas intended for automotive radar. The delivery includes design / development and production of antenna prototypes based on an updated antenna specification for a 77 GHz corner radar. The value of the order is 3MSEK with expected delivery to take place during the first quarter of 2022.Over the past year, HELLA has evaluated Gapwave's technology through several design and prototype projects. As a deepening of the collaboration, a license and development agreement were signed in June 2021 between Gapwaves and HELLA. As part

NextCell increases market potential and reduces the risk of ProTrans' clinical trial program in type 1 diabetes

NextCell Pharma AB ("NextCell" or the "Company") updates the strategy for the clinical trial program in type 1 diabetes with ProTrans. The aim is to increase potential while reducing the risk. This can be achieved by waiting for preliminary safetydata from the approved ProTrans-Young pediatric trial before submitting the application for ProTrans-3, scheduled for H2 2022.Advantages of the updated strategy for future application for marketing approval are: · Lower age limit for treatment is desirable and could potentially double the intitial market · Increased long term data from

New technology to reduce blood loss after injury

When a critical injury to an arm or leg results in intense blood loss, an emergency tourniquet must be applied. Through innovative solutions, competence in industrialisation and eco-design, Semcon in Norway is supporting health tech company Aristeia in the development of its unique tourniquet for bleeding control.Aristeia’s patented solution is easy and quick to use, providing a market leading pressure distribution thanks to the geared pull cord mechanism, the robust strap guide, and the on-device user instructions. The optimised pressure distribution reduces pain and discomfort.  “This

Tamro medicines go by PostNord’s biogas trucks – driven by climate goals and legislation governing the transport of medicines

Tamro’s logistics are driven by climate goals and legislation governing the transport of medicines and health products. With Tamro’s partner Post Nord’s biogas-powered vehicles, transport is safe, cost-effective and climate friendly.Some of the transports of Tamro, Finland’s leading medicines and health and wellbeing products distributor and service provider, reach customers with the help of Gasum biogas. Since Tamro’s customers can be found across Finland from large cities and built-up areas to the smallest localities, many transport kilometers are clocked up each week. Logistics are a

Hemsö acquires two nursing homes in Germany

Hemsö is acquiring two nursing homes, in two separate transactions, in the state of Bavaria in Germany. The investment amounts to EUR 28 million.The acquisitions consist of one nursing home in the city of Pullach, in the outskirts of Munich, and one nursing home in Pfronten, close to the Austrian border.  The facility in Pullach has been leased by Gemeinnützige Paritätische Altenhilfe in a 25-year rental agreement. The facility in Pfronten has been leased by Korian in a six-year rental agreement. “We are pleased with these acquisitions in Bavaria, a state where we want to grow our

Attendo’s report for the third quarter 2021: Increased demand and good organic growth

Attendo’s report for the third quarter of 2021 shows continued good organic growth and a higher operating profit compared to the same period of 2020. The improvement in profit is led by Scandinavia, where higher demand has led to a clear improvement in occupancy compared to the spring. In Finland, the improvement slowed down somewhat during the quarter, mainly due to temporary shortages of substitutes staff during the summer months.Comments from Martin Tivéus, president and CEO “After a long period defined by the pandemic, we are pleased that we have been able to fill more beds in

There are no items matching the current filter
There are no more items matching the current filter
Back to top